Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Iovance Biotherapeutics (0JDK) Share Price & Analysis

5 Followers

0JDK Stock Chart & Stats

$8.03$0.04(0.56%)
At close: 4:30 PM GMT
$7.5$10$12.5$15Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$7.98 - $8.33
52-Week Range
$2.09 - $17.25
Previous Close
$7.98
Volume
N/A
Average Volume (3M)
110.32K
Market Cap
$3.74B
Enterprise Value
$6.43B
Total Cash (Recent Filing)
$376.32M
Total Debt (Recent Filing)
$45.21M
Price to Earnings (P/E)
―
Beta
0.87
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.04
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Commercial Revenue Growth

Rapid revenue growth and more than 1,000 commercial patients treated indicate expanding adoption of AMTAGVI rather than an unlaunched pipeline story. Continued sequential growth and reaffirmed guidance improve commercial visibility while strengthening the base for broader treatment-center utilization.

Improving Gross Margin

Rising gross margin suggests that manufacturing scale, operational efficiencies, and disciplined investment are improving the economics of the commercial platform. If sustained, this trend can help AMTAGVI generate more contribution from each treatment and support progress toward eventual profitability.

Cash Runway

A cash runway extending well into 2029 gives Iovance time to expand AMTAGVI access, advance clinical programs, and pursue international approvals without immediate financing pressure. This supports strategic flexibility while the company works toward positive operating results.

Bears Say

Persistent Operating Losses

Iovance has not yet demonstrated sustainable earnings power despite commercial revenue growth, and management did not provide a timeline for profitability. Continued operating losses could constrain reinvestment choices and leave results dependent on further scale, margin gains, and disciplined expenses.

Negative Free Cash Flow

Ongoing cash consumption means the commercial business currently does not fund its own operations, even though burn has improved from earlier periods. Persistent negative free cash flow increases execution pressure and could eventually require additional funding if losses continue longer than expected.

International Reimbursement Delays

Pending reimbursement and regulatory steps may slow international access to AMTAGVI after approval and delay the conversion of overseas treatment-center capacity into broad commercial demand. This limits near-term geographic diversification and leaves expansion dependent on additional market-access execution.

Iovance Biotherapeutics News

0JDK FAQ

What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest share price was $2.09 and its highest was $17.25 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $3.74B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 110 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on Nov 05, 2026. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.034.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Iovance Biotherapeutics dividends here
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.04.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 462,655,150 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went down -10.357%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Hedge funds hold Iovance Biotherapeutics shares: the largest hedge-fund position in Iovance Biotherapeutics is 1,512,996,533 shares, and hedge funds increased their holdings by 45.2K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology